pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Cardiology · news · pharmadog
← back to Cardiology
News · Cardiology
332
stories
22d
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
22d
Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M
endpoints
22d
STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
stat
22d
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
22d
Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidance
fiercebiotech
22d
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
22d
Boston Scientific cuts guidance again after unveiling restructuring plan
fiercebiotech
23d
Recon: FDA adcomm votes against Capricor’s DMD drug; Cytokinetics gets UK approval, NICE backing for heart drug
raps
23d
FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
23d
FDA reviewers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
23d
Capricor Duchenne cell therapy voted down by FDA panel
biopharma dive
23d
FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute
fiercebiotech
23d
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
23d
Do you need oncology experience to land an oncology job?
biospace
23d
STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drug
stat
24d
STAT+: American Diabetes Association, facing calls for resignations, asks for patience
stat
24d
GSK shares rise as $2.5B cost-cutting plan unveiled
biospace
24d
After PCOS became PMOS, there’s hope for new awareness among Black and Latina women
stat
25d
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
biospace
25d
STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
stat
25d
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
25d
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
fiercebiotech
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
25d
American Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matter
fda medwatch
25d
Labcorp launches DTC ‘Genetic Health Panel’ to seek out multiple diseases
fiercebiotech
28d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
28d
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
biospace
28d
STAT+: Fatal gene-editing trial in China raises ethics and oversight questions
stat
28d
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
29d
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
← prev
page 4 of 12
next →
